A Phase 1b Dose Escalation Study of OMP-54F28 in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer
B
Bert O'Neil, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is is to test the effectiveness of a new drug to treat pancreatic cancer.
Description
The purpose of this study is is to test the effectiveness of a new drug to treat pancreatic cancer.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Pancreatic Cancer
-
Age: Between 18 Years - 90 Years
-
Gender: All
Updated on
25 Apr 2024.
Study ID: 1310585054
